ArticleBulletin of experimental biology and medicine2025
Infarct-Limiting Efficacy of K
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evaluation of the Role of Glucagon-Like Peptide-1 Receptors in the Infarction-Limiting and Inotropic Effects of Adaptation to Chronic Hypoxia in Rats with and without Metabolic Syndrome.Bulletin of experimental biology and medicine · 2026Article
- Dynamics of Endogenous Somatostatin and the Infarct-Limiting Effect of Octreotide in a Rat Model of Long-Term Ischemia/Reperfusion.Bulletin of experimental biology and medicine · 2025Article
- Declining nitric oxide bioavailability in cardiovascular aging: mechanistic insights and emerging interventions.The journal of cardiovascular aging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary occlusion (45 min) and reperfusion (2 h) were modeled, and the ratio of the necrosis area to area at risk ratio was measured in rats. Metabolic syndrome was induced by high-carbohydrate high-fat diet for 84 days. A single administration of diazoxide, nicorandil at a dose of 5 mg/kg or nitroglycerin at a dose of 0.24 mg/kg to animals without metabolic syndrome resulted in a decrease in infarct size. A 21-day course of diazoxide had no infarct-limiting effect. After course administration of nicorandil or nitroglycerin, we observed a trend toward a decrease in infarct size, which completely disappeared 2 weeks after the course of therapy. In rats with metabolic syndrome, no infarct-limiting effect of diazoxide, nicorandil, and nitroglycerin was revealed.
Indexed as
Identifiers
40679516What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.